PGP and neoplasm: In the following study, we intended to develop a combination of monoclonal P-glycoprotein (P-gp) antibodies and miR-122 loaded on graphene oxide InP@ZnS QDs (GPMQNs), which should promote drug-resistant tumor cell apoptosis and exhibit targeted controlled-release properties.